Formosa Optical Technology (5312) reported revenue of NT$430.6 million for Oct 2026, +14.7% year on year and +16.0% from the previous month. Revenue for Jan–Oct 2026 was NT$3.81 billion (+11.6% year on year).
Revenue for Oct 2026 was a record high (previous high: Mar 2026, NT$413.4 million). →
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 21 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$430.6 million | +14.7% | +16.0% |
| Sep 2026 | NT$371.3 million | +6.5% | -2.0% |
| Aug 2026 | NT$378.9 million | +4.8% | -3.6% |
| Jul 2026 | NT$393 million | +16.8% | +8.1% |
| Jun 2026 | NT$363.7 million | +9.5% | -5.1% |
| May 2026 | NT$383.2 million | +17.4% | +5.0% |
| Apr 2026 | NT$364.9 million | +14.0% | -11.7% |
| Mar 2026 | NT$413.4 million | +21.6% | +23.2% |
| Feb 2026 | NT$335.5 million | -0.4% | -10.9% |
| Jan 2026 | NT$376.5 million | +11.7% | -5.1% |
| Dec 2025 | NT$396.9 million | +16.1% | +5.4% |
| Nov 2025 | NT$376.4 million | +17.8% | +0.2% |
| Oct 2025 | NT$375.5 million | +12.9% | +7.7% |
| Sep 2025 | NT$348.8 million | +3.5% | -3.5% |
| Aug 2025 | NT$361.4 million | +1.7% | +7.4% |
| Jul 2025 | NT$336.5 million | +1.8% | +1.4% |
| Jun 2025 | NT$332 million | +3.1% | +1.7% |
| May 2025 | NT$326.3 million | -0.6% | +1.9% |
| Apr 2025 | NT$320.2 million | +1.8% | -5.8% |
| Mar 2025 | NT$339.9 million | -5.3% | +1.0% |
| Feb 2025 | NT$336.7 million | -2.0% | -0.1% |
| Jan 2025 | NT$336.9 million | +1.4% | -1.5% |
| Dec 2024 | NT$341.9 million | +6.0% | +7.0% |
| Nov 2024 | NT$319.5 million | -1.7% | -4.0% |
| Oct 2024 | NT$332.6 million | -2.4% | -1.3% |
Jan–Oct 2026 cumulative: NT$3.81 billion (+11.6% YoY)
Other Biotech & Medical companies
Compare with peers: Formosa Optical Technology vs PEC / Formosa Optical Technology vs Lotus Pharm / Formosa Optical Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
單月營收及累計營收再創歷史新高
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16